Merus N V Revenue Growth Rates (MRUS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Merus N v   (NASDAQ: MRUS)
 

MRUS's Revenue Growth by Quarter and Year

Merus N V 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MRUS Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September 12.15
2nd Quarter June 8.83
1st Quarter March 26.49
FY 47.47

MRUSs Annual Revenue
Merus N V 's Revenue in the fiscal year 2024 $ 36.13 millions
Merus N V 's Revenue in the fiscal year 2023 $ 43.95 millions
Merus N V 's Revenue in the fiscal year 2022 $ 41.59 millions
Merus N V 's Revenue in the fiscal year 2021 $ 49.11 millions
Merus N V 's Revenue in the fiscal year 2020 $ 29.94 millions




MRUS Revenue third quarter 2025 Y/Y Growth Comment
Merus N v reported Revenue growth of 3.23% year on year in the third quarter 2025, to $ 12.15 millions, this is lower than Merus N V 's recent average Revenue improvement of 20.03%.

Looking into third quarter 2025 results within Major Pharmaceutical Preparations industry 132 other companies have achieved higher Revenue growth. While Merus N V ' s Revenue increase of 3.23% ranks overall at the positon no. 2331 in the third quarter 2025.


MRUS Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - 2.24 % -16.21 % -27.46 %
3rd Quarter September 3.23 % 6.71 % 67.63 % -51.87 %
2nd Quarter June 20.46 % -30.06 % -17.35 % 2.42 %
1st Quarter March 235.74 % -41.56 % 15.78 % 39.64 %
FY   - -17.79 % 5.67 % -

Financial Statements
Merus N V 's third quarter 2025 Revenue $ 12.15 millions MRUS's Income Statement
Merus N V 's third quarter 2024 Revenue $ 11.77 millions Quarterly MRUS's Income Statement


MRUS Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - -22.34 % -18.95 % 62.16 %
3rd Quarter September 37.6 % 60.57 % 5.25 % -48.11 %
2nd Quarter June -66.67 % -7.1 % -22.37 % 8.75 %
1st Quarter March 189.82 % -11.74 % 26.52 % -20.73 %
FY (Year on Year)   - -17.79 % 5.67 % -


Back to MRUS Growth rate Comparisons >> Back to MRUS Growth rate Comparisons >>


Revenue third quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #133
Healthcare Sector #363
Overall #2331

Revenue Y/Y Growth Statistics
High Average Low
235.76 % 20.03 % -51.85 %
(Dec 31 2021)   (Jun 30 2023)
Revenue third quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #133
Healthcare Sector #363
Overall #2331
Revenue Y/Y Growth Statistics
High Average Low
235.76 % 20.03 % -51.85 %
(Dec 31 2021)   (Jun 30 2023)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Merus N V 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
189.8 % 12.47 % -66.67 %
(Mar 31 2025)  


MRUS's III. Quarter Q/Q Revenue Comment
Merus N v achieved in the III. Quarter 2025 above company average sequential Revenue jump of 37.6%, to $ 12.15 millions, from $8.83 millions in the second quarter.

Within Major Pharmaceutical Preparations industry 24 other companies have achieved higher Revenue quarter on quarter growth. While Merus N V 's Revenue growth quarter on quarter, overall rank is 140.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #25
Healthcare Sector #39
Overall #140
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #25
Healthcare Sector #39
Overall #140
Revenue Q/Q Growth Statistics
High Average Low
189.8 % 12.47 % -66.67 %
(Mar 31 2025)  


MRUS's III. Quarter Q/Q Revenue Comment
Merus N v achieved in the III. Quarter 2025 above company average sequential Revenue jump of 37.6%, to $ 12.15 millions, from $8.83 millions in the second quarter.

Within Major Pharmaceutical Preparations industry 24 other companies have achieved higher Revenue quarter on quarter growth. While Merus N V 's Revenue growth quarter on quarter, overall rank is 140.


Merus N V 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)
Cumulative Revenue 12 Months Ending $ 56.61 $ 56.23 $ 54.73 $ 36.13 $ 35.93
Y / Y Revenue Growth (TTM) 57.54 % 59.77 % 42.77 % -17.78 % -21.33 %
Year on Year Revenue Growth Overall Ranking # 2144 # 1350 # 2303 # 1000 # 610
Seqeuential Revenue Change (TTM) 0.67 % 2.73 % 51.47 % 0.56 % 2.1 %
Seq. Revenue Growth (TTM) Overall Ranking # 1409 # 1271 # 2323 # 1709 # 272


Cumulative Revenue growth Comment
Assuming the Merus N V 's fiscal year would have ended in Sep 30 2025, Merus N V would have reprted above average annual Revenue growth of 57.54% year on year, of $ 57 millions.
This marks a slow-down of the companys growth trends and from the 59.77% increase in Jun 30 2025.

In the Healthcare sector 290 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1350 to 2144.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 79
Healthcare Sector # 291
Overall # 2144

Revenue TTM Y/Y Growth Statistics
High Average Low
64 %
 13.54 %
-21.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 79
Sector # 223
S&P 500 # 1409
Cumulative Revenue growth Comment
Assuming the Merus N V 's fiscal year would have ended in Sep 30 2025, Merus N V would have reprted above average annual Revenue growth of 57.54% year on year, of $ 57 millions.
This marks a slow-down of the companys growth trends and from the 59.77% increase in Jun 30 2025.

In the Healthcare sector 290 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1350 to 2144.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 79
Healthcare Sector # 291
Overall # 2144

Revenue TTM Y/Y Growth Statistics
High Average Low
64 %
13.54 %
-21.81 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 79
Sector # 223
S&P 500 # 1409




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MRUS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2025
Integra Lifesciences Holdings Corp5.57%$ 5.574 millions
Myomo Inc 5.55%$ 5.552 millions
Iqvia Holdings Inc 5.24%$ 5.236 millions
Scientific Industries Inc 5.22%$ 5.216 millions
Henry Schein Inc 5.20%$ 5.198 millions
Pulmonx Corporation5.12%$ 5.123 millions
Baxter International Inc 5.04%$ 5.039 millions
Butterfly Network Inc 4.99%$ 4.992 millions
Ge Healthcare Technologies Inc 4.95%$ 4.952 millions
Orthofix Medical Inc 4.83%$ 4.830 millions
Davita Inc 4.80%$ 4.800 millions
Cvrx inc 4.78%$ 4.785 millions
Foghorn Therapeutics Inc 4.42%$ 4.419 millions
Acadia Healthcare Company Inc 4.41%$ 4.406 millions
Yunhong Green Cti Ltd 4.39%$ 4.394 millions
Seer Inc 4.37%$ 4.368 millions
Fonar Corporation4.34%$ 4.339 millions
Alkermes Plc 4.24%$ 4.242 millions
Lftd Partners Inc 4.20%$ 4.200 millions
Avanos Medical Inc 4.18%$ 4.179 millions
Biomarin Pharmaceutical Inc4.08%$ 4.076 millions
Inogen Inc 4.00%$ 4.003 millions
Enhabit Inc 3.94%$ 3.943 millions
Fortrea Holdings Inc 3.91%$ 3.912 millions
Pacific Health Care Organization Inc3.88%$ 3.879 millions
Merck and Co Inc 3.72%$ 3.716 millions
Brookdale Senior Living Inc 3.70%$ 3.698 millions
Enanta Pharmaceuticals Inc3.55%$ 3.546 millions
3m Company3.54%$ 3.543 millions
Teva Pharmaceutical Industries Limited3.44%$ 3.440 millions


About Merus N V Revenue Growth Rates (MRUS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.